Siyuan Hou1, Wei Yang. 1. Department of Hematology, Affiliated Shengjing Hospital of China Medical University, Shenyang, China.
Abstract
OBJECTIVE: To evaluate the curative effect of Rituximab combined CHOP chemotherapy in patients with non-Hodgkin lymphoma in China. METHODS: We conducted this study in the Affiliated Shengjing Hospital of China Medical University, Shenyang, China between June and December 2010. We used the systematic review method of The Cochrane Collaboration to collect randomized controlled trials (RCTs) of Rituximab combined CHOP chemotherapy for non-Hodgkin lymphoma by computer databases during the period 2004-2009. RESULTS: Seven trials involving 357 patients were retrieved. The complete remission rate of Rituximab combined CHOP chemotherapy was higher than that of CHOP chemotherapy alone (odds ratio = 3.02, 95% confidence interval: 1.94-4.72, p<0.00001). CONCLUSION: Non-Hodgkin lymphoma treated by Rituximab combined CHOP chemotherapy can produce a positive therapeutic effect in China.
OBJECTIVE: To evaluate the curative effect of Rituximab combined CHOP chemotherapy in patients with non-Hodgkin lymphoma in China. METHODS: We conducted this study in the Affiliated Shengjing Hospital of China Medical University, Shenyang, China between June and December 2010. We used the systematic review method of The Cochrane Collaboration to collect randomized controlled trials (RCTs) of Rituximab combined CHOP chemotherapy for non-Hodgkin lymphoma by computer databases during the period 2004-2009. RESULTS: Seven trials involving 357 patients were retrieved. The complete remission rate of Rituximab combined CHOP chemotherapy was higher than that of CHOP chemotherapy alone (odds ratio = 3.02, 95% confidence interval: 1.94-4.72, p<0.00001). CONCLUSION:Non-Hodgkin lymphoma treated by Rituximab combined CHOP chemotherapy can produce a positive therapeutic effect in China.
Authors: Jong Yeob Kim; Keum Hwa Lee; Michael Eisenhut; Hans J van der Vliet; Andreas Kronbichler; Gwang Hun Jeong; Jae Il Shin; Gabriele Gamerith Journal: Cancers (Basel) Date: 2019-11-15 Impact factor: 6.639